Literature DB >> 30076260

Getting site-specific with actomyosin inhibitors.

Laura K Gunther1, Christopher M Yengo2.   

Abstract

Actin and myosin play important roles in many devastating diseases and thus are attractive targets for small-molecule therapy. In this issue of JBC, Guhathakurta et al. have developed a high-throughput screening assay to find small molecules that interfere with the actomyosin interaction. They utilized time-resolved FRET (TR-FRET) and a unique donor-acceptor pair (filamentous actin and a peptide that binds near the myosin-binding site on actin) to find novel molecules that interfere with the actomyosin ATPase and alter the structure of actin filaments. These findings demonstrate the power and potential of high-throughput TR-FRET in monitoring molecular interactions.
© 2018 Gunther and Yengo.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 30076260      PMCID: PMC6078439          DOI: 10.1074/jbc.H118.004679

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  10 in total

Review 1.  Effects of hypertrophic and dilated cardiomyopathy mutations on power output by human β-cardiac myosin.

Authors:  James A Spudich; Tural Aksel; Sadie R Bartholomew; Suman Nag; Masataka Kawana; Elizabeth Choe Yu; Saswata S Sarkar; Jongmin Sung; Ruth F Sommese; Shirley Sutton; Carol Cho; Arjun S Adhikari; Rebecca Taylor; Chao Liu; Darshan Trivedi; Kathleen M Ruppel
Journal:  J Exp Biol       Date:  2016-01       Impact factor: 3.312

2.  A small-molecule inhibitor of sarcomere contractility suppresses hypertrophic cardiomyopathy in mice.

Authors:  Eric M Green; Hiroko Wakimoto; Robert L Anderson; Marc J Evanchik; Joshua M Gorham; Brooke C Harrison; Marcus Henze; Raja Kawas; Johan D Oslob; Hector M Rodriguez; Yonghong Song; William Wan; Leslie A Leinwand; James A Spudich; Robert S McDowell; J G Seidman; Christine E Seidman
Journal:  Science       Date:  2016-02-05       Impact factor: 47.728

3.  Fluorescence lifetime plate reader: resolution and precision meet high-throughput.

Authors:  Karl J Petersen; Kurt C Peterson; Joseph M Muretta; Sutton E Higgins; Gregory D Gillispie; David D Thomas
Journal:  Rev Sci Instrum       Date:  2014-11       Impact factor: 1.523

4.  High-throughput screen, using time-resolved FRET, yields actin-binding compounds that modulate actin-myosin structure and function.

Authors:  Piyali Guhathakurta; Ewa Prochniewicz; Benjamin D Grant; Kurt C Peterson; David D Thomas
Journal:  J Biol Chem       Date:  2018-06-04       Impact factor: 5.157

5.  Amplitude of the actomyosin power stroke depends strongly on the isoform of the myosin essential light chain.

Authors:  Piyali Guhathakurta; Ewa Prochniewicz; David D Thomas
Journal:  Proc Natl Acad Sci U S A       Date:  2015-03-30       Impact factor: 11.205

Review 6.  Pharmacologic Management for Heart Failure and Emerging Therapies.

Authors:  Diana H Kim; Feng-Ju Chien; Howard J Eisen
Journal:  Curr Cardiol Rep       Date:  2017-08-24       Impact factor: 2.931

7.  Skeletal muscle myosin light chains are essential for physiological speeds of shortening.

Authors:  S Lowey; G S Waller; K M Trybus
Journal:  Nature       Date:  1993-09-30       Impact factor: 49.962

8.  The structural dynamics of actin during active interaction with myosin depends on the isoform of the essential light chain.

Authors:  Ewa Prochniewicz; Piyali Guhathakurta; David D Thomas
Journal:  Biochemistry       Date:  2013-02-15       Impact factor: 3.162

Review 9.  Myosins: Domain Organisation, Motor Properties, Physiological Roles and Cellular Functions.

Authors:  Thomas A Masters; John Kendrick-Jones; Folma Buss
Journal:  Handb Exp Pharmacol       Date:  2017

Review 10.  Non-muscle myosin II in disease: mechanisms and therapeutic opportunities.

Authors:  Karen A Newell-Litwa; Rick Horwitz; Marcelo L Lamers
Journal:  Dis Model Mech       Date:  2015-11-05       Impact factor: 5.758

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.